ACHV vs. LXRX, VNDA, EBS, AGEN, XOMA, CDXS, RIGL, RGLS, SGMO, and VSTM
Should you be buying Achieve Life Sciences stock or one of its competitors? The main competitors of Achieve Life Sciences include Lexicon Pharmaceuticals (LXRX), Vanda Pharmaceuticals (VNDA), Emergent BioSolutions (EBS), Agenus (AGEN), XOMA (XOMA), Codexis (CDXS), Rigel Pharmaceuticals (RIGL), Regulus Therapeutics (RGLS), Sangamo Therapeutics (SGMO), and Verastem (VSTM). These companies are all part of the "biotechnology" industry.
Lexicon Pharmaceuticals (NASDAQ:LXRX) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk, institutional ownership and community ranking.
74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 4.5% of Lexicon Pharmaceuticals shares are owned by company insiders. Comparatively, 2.0% of Achieve Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Lexicon Pharmaceuticals had 3 more articles in the media than Achieve Life Sciences. MarketBeat recorded 7 mentions for Lexicon Pharmaceuticals and 4 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 0.94 beat Lexicon Pharmaceuticals' score of 0.76 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.
Lexicon Pharmaceuticals has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.
Lexicon Pharmaceuticals presently has a consensus target price of $6.67, suggesting a potential upside of 287.60%. Achieve Life Sciences has a consensus target price of $14.00, suggesting a potential upside of 181.12%. Given Achieve Life Sciences' higher possible upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Achieve Life Sciences.
Achieve Life Sciences has a net margin of 0.00% compared to Achieve Life Sciences' net margin of -8,311.12%. Achieve Life Sciences' return on equity of -108.54% beat Lexicon Pharmaceuticals' return on equity.
Lexicon Pharmaceuticals received 136 more outperform votes than Achieve Life Sciences when rated by MarketBeat users. However, 70.21% of users gave Achieve Life Sciences an outperform vote while only 64.54% of users gave Lexicon Pharmaceuticals an outperform vote.
Achieve Life Sciences has lower revenue, but higher earnings than Lexicon Pharmaceuticals. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Lexicon Pharmaceuticals beats Achieve Life Sciences on 12 of the 16 factors compared between the two stocks.
Get Achieve Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACHV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Achieve Life Sciences Competitors List
Related Companies and Tools
